Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus
Clinical Transplantation · 2023
DOI: 10.1111/ctr.14941 ↗At a glance
Journal article in Clinical Transplantation, 2023. Written by David J Taber and 11 co-authors. Institution: Department of Surgery, Division of Transplant Surgery, MUSC, Charleston, South Carolina, USA. Major MEDLINE topics: Tacrolimus, Kidney Transplantation. Cited 5 times so far (Crossref); 22 references.
Abstract (original language)
Background
The influence of converting to once daily, extended‐release LCP‐Tacrolimus (Tac) for those with high tacrolimus variability in kidney transplant recipients (KTRs) is not well‐studied.
Methods
Single‐center, retrospective cohort study of adult KTRs converted from Tac immediate release to LCP‐Tac 1‐2 years post‐transplant. Primary measures were Tac variability, using the coefficient of variation (CV) and time in therapeutic range (TTR), as well as clinical outcomes (rejection, infections, graft loss, death).
Results
A total of 193 KTRs included with a follow‐up of 3.2 ± .7 years and 1.3 ± .3 years since LCP‐Tac conversion. Mean age was 52 ± 13 years; 70% were African American, 39% were female, 16% living donor and 12% donor after cardiac death (DCD). In the overall cohort, tac CV was 29.5% before conversion, which increased to 33.4% after LCP‐Tac ( p = .008). In those with Tac CV >30% ( n = 86), conversion to LCP‐Tac reduced variability (40.6% vs. 35.5%; p = .019) and for those with Tac CV >30% and nonadherence or med errors ( n = 16), LCP‐Tac conversion substantially reduced Tac CV (43.4% vs. 29.9%; p = .026). TTR significantly improved for those with Tac CV >30% with (52.4% vs. 82.8%; p = .027) or without nonadherence or med errors (64.8% vs. 73.2%; p = .005). CMV, BK, and overall infections were significantly higher prior to LCP‐Tac conversion. In the overall cohort, 3% had rejection before conversion and 2% after ( p = NS). At end of follow‐up, graft and patient survival were 94% and 96%, respectively.
Conclusions
In those with high Tac CV, conversion to LCP‐Tac is associated with a significant reduction in variability and improvement in TTR, particularly in those with nonadherence or medication errors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, Division of Transplant Surgery, MUSC, Charleston, South Carolina, USA.
- Department of Pharmacy Services, MUSC, Charleston, South Carolina, USA.
- College of Medicine, MUSC, Charleston, South Carolina, USA.
- Department of Medicine, Division of Nephrology, MUSC, Charleston, South Carolina, USA.
ORCID profiles: Neha Patel, Shikha Patel, Maria Aurora Posadas Salas
Cite
APA
Taber, D. J., Bartlett, F., Patel, N., Sprague, T., Patel, S., Newman, J., Andrade, E., Rao, N., Salas, M. A. P., Casey, M., Dubay, D., & Rohan, V. (2023). Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus. Clinical Transplantation. https://doi.org/10.1111/ctr.14941
Vancouver
Taber DJ, Bartlett F, Patel N, Sprague T, Patel S, Newman J, et al. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus. Clinical Transplantation. 2023. doi:10.1111/ctr.14941
BibTeX
@article{Taber2023,
author = {Taber, David J and Bartlett, Felicia and Patel, Neha and Sprague, Taylor and Patel, Shikha and Newman, Jessica and Andrade, Erika and Rao, Nikhil and Salas, Maria Aurora Posadas and Casey, Michael and Dubay, Derek and Rohan, Vinayak},
title = {Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP‐Tacrolimus},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.14941}
}
EUVIMED